Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202
| Autor: | Meena Bedi, Howard M. Sandler, James J. Dignam, Seth A. Rosenthal, Colleen A. Lawton, Harold Kim, Xiaolei Lin, Harmar D. Brereton, Young Kwok, Rachel Rabinovitch, Eric M. Horwitz, Matthew Parliament, Varagur Venkatesan, Thomas M. Pisansky, David J. Grignon, Kenneth L. Zeitzer, Gerald E. Hanks, Herbert Lepor, Mack Roach |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty 030218 nuclear medicine & medical imaging Flutamide Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Prostate Internal medicine medicine Radiology Nuclear Medicine and imaging Radiation business.industry Goserelin Cancer medicine.disease Prostate-specific antigen medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Adenocarcinoma business medicine.drug |
| Zdroj: | Lawton, CAF; Lin, X; Hanks, GE; Lepor, H; Grignon, DJ; Brereton, HD; et al.(2017). Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. International Journal of Radiation Oncology Biology Physics, 98(2), 296-303. doi: 10.1016/j.ijrobp.2017.02.004. UCSF: Retrieved from: http://www.escholarship.org/uc/item/2hv212wt |
| Popis: | © 2017 Purpose Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate. Long-term follow-up results of this study now available are relevant to the management of this disease. Methods and Materials Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|